SBIR Phase II: A Novel Antimicrobial Polymer for Medical Devices

SBIR II 期：用于医疗器械的新型抗菌聚合物

• 批准号: 1058279
• 负责人: Michael Szycher
• 金额: $ 49.99万
• 依托单位: STERLING BIOMEDICAL, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2012-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1058279&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Novel; Antimicrobial

This Small Business Innovation Research (SBIR) Phase II project aims to develop an antimicrobial polymer technology with silver compounded into the catheter matrix, which allows for antimicrobial action expected to last several months. This cost-effective antimicrobial polymer technology prevents the formation of surface biofilms on long-term implantable devices, without generating bacterial resistance. The root cause of these infections is the bacterial colonization of the catheter, with the likelihood of infection increasing as a function of catheter implantation time. Currently, there are no low-cost, long-term antimicrobial catheters, thus the proposed technology would fill a much needed clinical demand.The broader/commercial impact of this project addresses the 280,000 catheter-related bloodstream infections in the U.S. that cost over $3 billion per year in excess healthcare costs, claiming 80,000 deaths. The proposed technology will help clinicians attain and sustain zero indwelling catheter bloodstream infections. The $1.2 billion implantable device market urgently needs inherently antimicrobial catheters, thus obviating the need for systemic antibiotic treatment. Since no expensive coating procedures have to be performed, it will lead to cost effective manufacturing. This should lead to rapid commercialization of a family of antimicrobial catheters, especially since these advanced catheters will significantly help to reduce outcome costs.

这一小型企业创新研究（SBIR）第二阶段项目旨在开发一种抗菌聚合物技术，将银化合到导管基质中，从而实现预期持续数月的抗菌作用。 这种具有成本效益的抗菌聚合物技术可防止长期植入式器械表面生物膜的形成，而不会产生细菌耐药性。 这些感染的根本原因是导管的细菌定植，感染的可能性随着导管植入时间的增加而增加。 目前，还没有低成本、长期的抗菌导管，因此提出的技术将满足急需的临床需求。该项目的更广泛/商业影响解决了美国280，000例导管相关血流感染，每年花费超过30亿美元的额外医疗费用，造成80，000人死亡。 这项技术将帮助临床医生实现并维持零留置导管血流感染。 12亿美元的植入式器械市场迫切需要固有的抗菌导管，从而避免了对全身抗生素治疗的需求。 由于不需要执行昂贵的涂覆程序，因此这将导致成本有效的制造。 这将导致抗菌导管系列的快速商业化，特别是因为这些先进的导管将显着有助于降低结果成本。